Latest News

February 21, 2014

ITN Launches the PAUSE Study in Psoriasis

Today the ITN launched the PAUSE study (ITN059AI, “Efficacy of Ustekinumab followed by Abatacept for the Treatment of Psoriasis Vulgaris”), which will test the combination of two biologics, ustekinumab (Janssen Biotech, Inc.) and abatacept (Bristol-Myers Squibb), in psoriasis patients. This study is being led by James Krueger, MD, PhD (The Rockefeller University).

February 18, 2014

Specimens and Funding for Type 1 Diabetes Biomarker Research

Creating durable disease remission in type 1 diabetes has proved challenging: etiology remains uncertain and immune interventions have only been able to delay disease progression temporarily. To better understand underlying disease pathways, the ITN conducts sophisticated mechanistic assays on high-quality specimens collected from each of its clinical trials.

February 17, 2014

New Publication: T Cell Reconstitution Following Autologous Stem Cell Transplant in Patients with Multiple Sclerosis

The promise of autologous stem cell transplantation in patients with autoimmune disease is that the newly reconstituted immune system will be reset in a way that no longer favors autoimmunity. The ITN’s HALT-MS study (High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis) used high-dose immunosuppression followed by an autologous stem cell transplant in 24 relapsing, remitting multiple sclerosis (MS) patients in an attempt to reconstitute a healthy immune system.

January 15, 2014

ITN wins NIH award for Collaborative Network for Tolerance Research

The National Institute of Allergy and Infectious Disease (NIAID/NIH) announced that the Immune Tolerance Network (ITN) has been awarded a UM1 grant for a Collaborative Network for Clinical Research on Immune Tolerance (RFA-AI-12-043). This award represents the third NIH funding disbursement since the ITN’s inception in 2000.

January 6, 2014

ACCEPTOR Kidney Transplant Study Opens for Enrollment

The ITN’s ACCEPTOR study (Post-transplant Cyclophosphamide) in kidney transplant is now open for enrollment at Johns Hopkins University.  The ACCEPTOR study, led by Lode Swinnen, MD, Ephraim Fuchs, MD, and Robert Montgomery, MD (Johns Hopkins Hospital) will combine hematopoietic stem cell (HSC) and kidney transplants as a means to potentially promote tolerance to the donor kidney.  This approach to solid organ transplant aims to induce the stable presence of both host and donor immune systems simultaneously, called “mixed chimeri

December 13, 2013

The Immune Tolerance Network Opens ANCA-associated Vasculitis Biomarker Study in the UK

The ITN’s AVATARS study in ANCA-associated Vasculitis (AAV) opened for enrollment today at the University College London.

December 2, 2013

ITN Type 1 Diabetes Roundup at the International Diabetes Federation (IDF) and Immunology of Diabetes Society (IDS) Meetings

The International Diabetes Federation (IDF) annual meeting (December 2-6, 2013) and Immunology of Diabetes Society (IDS) annual meeting (December 7-11, 2013) in Australia will feature multiple talks on recent findings from the Immune Tolerance Network's ( ITN’s) portfolio of type 1 diabetes studies. Type 1 diabetes is a challenging disease where so far no therapeutic has been able to reverse or permanently halt the autoimmune attack on pancreatic β-cells.

October 24, 2013

Data from ITN Lupus Nephritis Study to be presented at Upcoming Rheumatology and Nephrology Conferences

Clinical data from the ITN’s ACCESS study (Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis) will be presented at two upcoming conferences.

October 4, 2013

ITN TrialShare Absorbs BioShare

The Immune Tolerance Network (ITN) is retiring ITN BioShare. ITN’s inventory of clinical trial biospecimens is now available through ITN TrialShare. Now that ITN’s biorepository is accessible through TrialShare, all web traffic to BioShare will redirect to www.ITNTrialShare.org.Launched in November of 2010, BioShare was ITN’s initial interface for sharing clinical samples collected from ITN trials with the scientific community.

September 23, 2013

New Publication: Results from the T1DAL Type 1 Diabetes Study

Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes), led by Dr. Mark Rigby (Indiana University) are published today in The Lancet Diabetes & Endocrinology.Alefacept, an engineered fusion protein targeting a surface molecule, CD2, found on T lymphocytes, was the first biologic therapy approved for moderate to severe plaque psoriasis. By binding CD2, alefacept inhibits co-stimulation and induces T cell depletion.